| scholarly article | Q13442814 |
| P50 | author | Michael Hallek | Q20752664 |
| Valentin Goede | Q47158799 | ||
| Stephan Stilgenbauer | Q47158807 | ||
| Hartmut Döhner | Q66385451 | ||
| P2093 | author name string | Raymonde Busch | |
| Robert Rohrberg | |||
| Carmen D Schweighofer | |||
| Anna-Maria Fink | |||
| Kirsten Fischer | |||
| Martina Stauch | |||
| Valentin Goede | |||
| Matthias Ritgen | |||
| Anne Westermann | |||
| Barbara F Eichhorst | |||
| Bertold Emmerich | |||
| Clemens M Wendtner | |||
| German CLL Study Group (GCLLSG) | |||
| Günter Brittinger | |||
| Manuela A Bergmann | |||
| Nicole Kranzhöfer | |||
| Oswald Burkhard | |||
| Ulrike Söling | |||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chlorambucil | Q415939 |
| leukemia | Q29496 | ||
| lymphocyte | Q715347 | ||
| P304 | page(s) | 3382-3391 | |
| P577 | publication date | 2009-07-15 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia | |
| P478 | volume | 114 |
| Q37321917 | A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia |
| Q38231432 | A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. |
| Q37609420 | A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia |
| Q33880538 | A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia |
| Q38579008 | Advances in first-line treatment of chronic lymphocytic leukemia: current recommendations on management and first-line treatment by the German CLL Study Group (GCLLSG). |
| Q38866636 | Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial |
| Q31096565 | An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data |
| Q34405641 | Anti-CD37 antibodies for chronic lymphocytic leukemia |
| Q39154824 | Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). |
| Q55056539 | Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. |
| Q38700745 | Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose? |
| Q37480786 | Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block |
| Q59126180 | Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia |
| Q37738533 | Challenges in the frontline treatment of patients with chronic lymphocytic leukemia |
| Q84904774 | Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in |
| Q33394947 | Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia |
| Q34879367 | Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712 |
| Q24236385 | Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphoma |
| Q38776166 | Chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL) - a systematic review and meta-analysis of randomized trials |
| Q36826208 | Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience |
| Q38424831 | Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial |
| Q47094907 | Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification |
| Q52646820 | Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. |
| Q38202645 | Chlorambucil-induced acute interstitial pneumonitis |
| Q35124844 | Choosing first-line therapy for chronic lymphocytic leukemia. |
| Q87869046 | Chronic lymphocytic leukaemia |
| Q38101683 | Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy |
| Q37903038 | Chronic lymphocytic leukemia in less fit patients: "slow-go". |
| Q34272532 | Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model |
| Q36826893 | Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 |
| Q37902948 | Chronic lymphocytic leukemia: an update on biology and treatment. |
| Q36609259 | Chronic lymphocytic leukemia: inception to cure: are we there? |
| Q34560909 | Chronic lymphocytic leukemia: planning for an aging population |
| Q37734199 | Chronic lymphocytic leukemia: putting new treatment options into perspective |
| Q48085869 | Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia |
| Q35110582 | Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia |
| Q88804876 | Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib |
| Q40981068 | Complete response to temozolomide in chronic lymphocytic leukemia. |
| Q40374202 | Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada |
| Q38877098 | Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy. |
| Q43242768 | Current and emerging treatments for chronic lymphocytic leukaemia |
| Q38676574 | Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia |
| Q36397924 | Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US i |
| Q37429218 | Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. |
| Q38061883 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). |
| Q40084503 | Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group |
| Q38792651 | Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States |
| Q37284001 | Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain |
| Q38660743 | Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis |
| Q39227230 | Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. |
| Q37185372 | Emerging drug profile: cyclin-dependent kinase inhibitors |
| Q41351036 | Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group |
| Q54108755 | Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. |
| Q38764077 | Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting |
| Q37672029 | Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario |
| Q50055654 | Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies |
| Q64092443 | First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 |
| Q33956034 | First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab |
| Q30891802 | First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis |
| Q35794457 | Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach |
| Q55360943 | Frailty in Hematologic Malignancy. |
| Q37964914 | Front-line therapy for chronic lymphocytic leukemia |
| Q47359917 | Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis |
| Q92715263 | Frontline therapies for untreated chronic lymphoid leukemia |
| Q45208503 | Highlights in the treatment of chronic lymphocytic leukemia from the 2013 meeting of the American Society of Hematology |
| Q34137158 | How I treat CLL up front |
| Q35814897 | IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia |
| Q36490049 | Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia |
| Q33412064 | Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial |
| Q26865561 | Immune reconstitution in chronic lymphocytic leukemia |
| Q37065666 | Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies |
| Q38673560 | Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy |
| Q42277456 | Infectious complications in chronic lymphocytic leukemia |
| Q38489690 | Integrating oncogeriatric tools into the management of chronic lymphocytic leukemia: current state of the art and challenges for the future. |
| Q33695990 | Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials |
| Q34009041 | Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia |
| Q34008584 | Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia |
| Q38106157 | Leukaemias into the 21st century. Part 2: the chronic leukaemias |
| Q90813107 | Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study |
| Q48751476 | Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. |
| Q30243914 | Management of elderly and unfit patients with chronic lymphocytic leukemia |
| Q39420524 | Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil |
| Q35889836 | MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia |
| Q33913537 | Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups |
| Q44078664 | Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia |
| Q37605306 | New Pharmacotherapies in Chronic Lymphocytic Leukemia |
| Q91599187 | New Treatments for Chronic Lymphocytic Leukemia |
| Q37147789 | New insights into biology, prognostic factors, and current therapeutic strategies in chronic lymphocytic leukemia |
| Q38190095 | New treatment options for chronic lymphocytic leukemia. |
| Q42643066 | Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers |
| Q53463137 | Obinutuzumab for chronic lymphocytic leukemia. |
| Q38569094 | Obinutuzumab in chronic lymphocytic leukemia |
| Q26799205 | Obinutuzumab in hematologic malignancies: lessons learned to date |
| Q38537523 | Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia |
| Q37845824 | Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia |
| Q26738934 | Ofatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association data |
| Q90028953 | On the architecture of translational research designed to control chronic lymphocytic leukemia |
| Q37844139 | Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly |
| Q36779681 | Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). |
| Q38248969 | Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia |
| Q38851368 | Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future? |
| Q54612791 | Personalizing treatment for chronic lymphocytic leukemia. |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q38601727 | Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope |
| Q36845277 | Practical approach to management of chronic lymphocytic leukemia |
| Q26781163 | Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia |
| Q91708724 | Prognosis Factors in Chronic Lymphocytic Leukemia |
| Q38345576 | Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q45708911 | Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial |
| Q36443141 | Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia |
| Q42097243 | Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial). |
| Q52560286 | Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. |
| Q35714606 | Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis |
| Q90589544 | Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials |
| Q37141887 | Risk categories and refractory CLL in the era of chemoimmunotherapy |
| Q41241909 | Rituximab for the treatment of patients with chronic lymphocytic leukemia |
| Q35123154 | Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study |
| Q37799820 | Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia |
| Q88257800 | Role and timing of new drugs in CLL |
| Q38490482 | Role of obinutuzumab in the treatment of chronic lymphocytic leukemia |
| Q30801095 | Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms |
| Q37865547 | Salvage therapy for relapsed chronic lymphocytic leukemia |
| Q38893343 | Secondary immunodeficiency in lymphoproliferative malignancies. |
| Q30240243 | Sequencing of chronic lymphocytic leukemia therapies. |
| Q37742056 | Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia |
| Q58776981 | Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 |
| Q27001163 | Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials |
| Q38574045 | Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies |
| Q64263185 | The Treatment of Chronic Lymphatic Leukemia |
| Q42920639 | The addition of rituximab to fludarabine and cyclophosphamide improves progression-free survival in patients with previously treated chronic lymphocytic leukemia. |
| Q38126946 | The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy |
| Q24605471 | The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies |
| Q30243968 | The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia |
| Q36300303 | Therapeutic advancement of chronic lymphocytic leukemia |
| Q37974861 | Treatment of older patients with chronic lymphocytic leukemia |
| Q36612587 | Treatment options for high-risk chronic lymphocytic leukaemia |
| Q34157931 | U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia |
| Q33406478 | Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis |
| Q38246230 | Update on obinutuzumab in the treatment of B-cell malignancies |
| Q37659071 | Update on therapy of chronic lymphocytic leukemia |
| Q92218684 | Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma |
| Q91704947 | Validation of the Chinese EORTC chronic lymphocytic leukaemia module - application of classical test theory and item response theory |
| Q38063170 | What do we do with chronic lymphocytic leukemia with 17p deletion? |
| Q37820433 | What is the best frontline therapy for patients with CLL and 17p deletion? |
| Q86033602 | [Chronic lymphocytic leukemia. Treatment and genetic risk profile] |
| Q83653982 | [Malignant lymphomas: clinical appearance, classification, therapy and prognosis] |
Search more.